The ZINFORO® Patient

Ceftaroline fosamil (Zinforo®): cSSTI Patient profiles

Identifying a cSSTI patient who may benefit from Zinforo®

In cSSTI patients, initial antimicrobial therapy failure is associated with 4-11 days longer in hospital and 4-12x higher mortality2·4

Laura, a 71-year-old, with diabetes and cellulitis, presented with tender erythematous, non-raised lesions*

Severity

  • Deep and extensive cellulitis on the right leg that extends mid-calf to the ankle (~275 cm2)
  • Signs of systemic inflammatory response - Temp >38°C
  • Rapid spread of erythema over past 24 hours

History/comorbidities

  • History of smoking
  • Type 2 insulin-dependent diabetes HbA1c = 7.4%

Risk factors for difficult-to-treat infection

  • Nursing home resident
  • Comorbidity associated with impaired immune response (DM)

Martin, a 44-year-old, readmitted to the hospital following inguinal hernia repair with purulent drainage from incision and localised pain*

Severity

  • Signs of systemic inflammatory response
    - Temperature >38°C
    - Heart rate >90 bpm

History/Comorbidities

  • History of depression (currently controlled by medication)
  • Obese
    - Weight = 132 kg
    - BMI = 37 kg/m2

Risk factors for difficult-to-treat infection

  • MRSA colonisation identified during admission screening for surgery

Mark, a 67-year-old, admitted to the emergency room with a painful and fluctuant gluteal abscess*

Severity

  • Abscess area of 12 cm2 , with a 95 cm2 surrounding cellulitis
  • Rapidly spreading infection
  • Signs of systemic inflammatory response
    - Temperature >38°C
    - Heart rate >90 bpm
    - RR >20/min
  • May be required to be moved to the ICU in the next 24 hours

History/Comorbidities

  • Chronic renal impairment
    - CrCl at hospital admission = 17 mL/min

Risk factors for difficult-to-treat infection

  • Immunocompromised as a result of comorbid chronic renal disease
  • Treatment with fluoroquinolone within 6 months for UTI​

 

Please note: The examples described here are not actual patients, but fictitious representations of scenarios for which Ceftaroline fosamil (Zinforo®) could be considered.

tRefer to Local product Document for further information on Zinforo.1

BMI: body mass index; CrCl: creatinine clearance; Cssti: complicated skin and soft tissue infections; DM: diabetes mellitus; HbA1c: hemoglobin A1c; ICU: intensive care unit; MRSA: methicillin-resistant Staphylococcus aureus; RR: respiratory rate; UTI: urinary tract infection.

References:
1. ZINFORO® (ceftaroline fosamil). Local Product Document of Ceftaroline; LPDZIN072021;
2. Berger A, et al. Surg Infect 2013;14;304-12;
3. Edelsberg J, et al. Infect Control Hosp Epidemiol 2008;29:160-9;
4. Ostermann H, et al. J Med econ 2013;17:719-29.

How do you identify your Zinforo® patients with cSSTI?*1-5

Zinforo® cSSTI patient profiles*6,7

Patient 1: Diabetic patient with cSSTI

A 62-year-old female with diabetes presents with deep and extensive cellulitis on the right leg that extends from mid-calf to the ankle.

Patient presentation, history and risk factors

  • Tender, erythematous, non-raised skin lesions
  • Rapid spread of infection over the past 24 hours
  • Patient weight = 102 kg
  • BMI = 36 kg/m2
  • Elevated blood cholesterol
  • HbA1c = 7.4%
  • History of smoking
  • Lives in a nursing home
  • Recent use of an old cephalosporin for a skin lesion 3 weeks ago

Patient 2: cSSTI patient with renal insufficiency^

A 67-year-old male presents with a painful, fluctuant and gluteal abscess.

Patient presentation, history and risk factors:

  • Rapidly spreading infection
  • Patient is deteriorating; may be required to be moved to the ICU in the next 24 hours
  • Severe renal insufficiency (CrCl at hospital admission: 17 mL/min)
  • CrCl falling rapidly
  • History of renal disease
  • History of prior antibiotic use

Please note: The examples described here are not actual patients, but fictitious representations of the scenarios for which Zinforo® could be considered.

*There is no experience with Zinforo® in the treatment of cSSTI in the following patient groups:
The immunocompromised, patients with severe sepsis/septic shock, necrotising fasciitis, perirectal abscess and patients with third-degree and extensive burns. There is limited experience in treating patients with diabetic foot infections. Caution is advised when treating such patients.8

^Zinforo® is primarily excreted by the kidneys and the dose should be reduced in patients with moderate to severe renal insufficiency. 8

cSSTI: complicated skin and soft tissue infections; BMI: body mass index; CrCl: creatinine clearance; HbA1c: hemoglobin A1c; ICU: intensive care unit.

References:
1. Corey G, Wilcox M, Talbot G, et al. Clin Infect Dis 2010; 51:641–50.
2. Santos PD, Davis A, Jandourek A, et al. J Chemother 2013;25:341–6.
3. Stein GE, Wallace S, Jandourek A, et al. Ceftaroline fosamil for treatment of cSSTI due to Staphylococcus aureus with vancomycin MICs of 1.5 to 2 mg/L: CAPTURE Study Experience.
4. Corey G, Wilcox M, Talbot G, et al. J Antimicrob Chemother 2010;65(Suppl. 4):iv41–iv51.
5. Wilcox M, Corey G, Talbot G, et al. J Antimicrob Chemother 2010;65(Suppl. 4):iv53–iv65. Evans J, Udeani G, Cole P, et al. Postgrad Med 2014; 126:128–34.
6. Maggiore C, Pasquale T, Cole P, et al. Expert Rev Clin Pharmacol 2015; 8:141–53.
7. Lipsky BA, Cannon CM, Ramani A, et al. Diabetes Metab Res Rev 2015; 31:395–401.
8. ZINFORO® (ceftaroline fosamil). Local Product Document of Ceftaroline; LPDZIN072021.

PP-ZFO-IND-0279.  09 December 2021
Please click on Prescribing Information link to view safety and adverse events information of Zinforo.
For the use only of registered medical practitioner, or a hospital or a laboratory.